Related Experiment Video
Updated: Apr 19, 2026
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Adherence to anti-Tuberculosis treatment during the COVID-19 pandemic: a single-centre, retrospective analysis
Filippo Ducci1, Francesco Enrico Bernardini2, Filippo Lagi3
1Unit of Infectious Diseases, San Jacopo Hospital, Azienda USL Toscana Centro, Via Ciliegiole 97, 51100, Pistoia, Italy.
Introduction:
Adherence to tuberculosis (TB) treatment is essential to achieve favourable outcomes, yet difficult to evaluate. Our study evaluates adherence using pharmacy refill data, and assesses COVID-19 pandemic's impact on TB care cascade.
Materials And Methods:
We retrospectively analysed patients diagnosed with TB at our unit in Florence (Italy) between January 2020 and December 2023. Adherence was measured using the Proportion of Days Covered (PDC) and compared with self-reported adherence and attendance at follow-up visits. PDC was calculated for the intensive (PDC1) and continuation phase (PDC2), and overall treatment (PDC). Data were compared between the pandemic (2020-2021) and post-pandemic (2022-2023) periods.
Results:
Among 135 subjects, 73.3% had a favourable outcome. Lost-to-follow-up patients (14.8%) more frequently included transgender, foreign-born and HIV-coinfected individuals. Mean PDC was 0.67; 74.5% of patients exhibited PDC<1. Adherence was lower during the continuation phase (PDC2 = 0.84) compared to the intensive phase (PDC1 = 0.94). PDC and PDC1 were significantly lower during the pandemic. Non-adherent patients reported more missed doses and skipped appointments.
Conclusions:
PDC is a simple, cost-effective tool to monitor adherence, that correlates well with self-reported adherence and follow-up visits attendance. TB treatment adherence remains suboptimal and the COVID-19 pandemic further exacerbated barriers to care, particularly among vulnerable populations such as migrants.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...